WallStSmart

Teva Pharma Industries Ltd ADR (TEVA)vsTalphera Inc. (TLPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 61635614% more annual revenue ($17.26B vs $28,000). TEVA leads profitability with a 8.2% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 73/100 (B).

TEVA

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 7.5Value: 10.0Quality: 4.8
Piotroski: 6/9Altman Z: 0.28

TLPH

Avoid

23

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TEVAUndervalued (+39.4%)

Margin of Safety

+39.4%

Fair Value

$56.63

Current Price

$29.46

$27.17 discount

UndervaluedFair: $56.63Overvalued

Intrinsic value data unavailable for TLPH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TEVA4 strengths · Avg: 8.3/10
Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
27.3%8/10

Strong operational efficiency at 27.3%

EPS GrowthGrowth
40.0%8/10

Earnings expanding 40.0% YoY

Free Cash FlowQuality
$1.02B8/10

Generating 1.0B in free cash flow

TLPH1 strengths · Avg: 8.0/10
Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

TEVA1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

TLPH4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$34.03M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : TEVA

The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bull Case : TLPH

The strongest argument for TLPH centers on Price/Book.

Bear Case : TEVA

The primary concerns for TEVA are Altman Z-Score.

Bear Case : TLPH

The primary concerns for TLPH are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

TEVA carries more volatility with a beta of 0.72 — expect wider price swings.

TEVA is growing revenue faster at 11.4% — sustainability is the question.

TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TEVA scores higher overall (73/100 vs 23/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Talphera Inc.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Talphera Inc. is a pioneering biotechnology firm specializing in the development of advanced therapies targeting rare diseases and significant unmet medical needs. The company leverages its expertise in peptide-based therapeutics to address critical challenges in cancer treatment and other high-need health areas. With a robust pipeline of innovative therapeutic candidates and a strong dedication to research excellence, Talphera is well-positioned for transformative contributions to the healthcare sector. For institutional investors, Talphera represents a compelling opportunity to engage with a growth-oriented company in the expanding biotechnology landscape.

Want to dig deeper into these stocks?